TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas

IDH mutations frequently occur in WHO grade II and III diffuse gliomas and have favorable prognosis compared to wild-type tumors. However, whether IDH mutations in WHO grade II and II diffuse gliomas predict enhanced sensitivity to adjuvant radiation (RT) or chemotherapy (CHT) is still being debated...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhen-Yu, Chan, Aden Ka-Yin, Ding, Xiao-Jie, Qin, Zhi-Yong, Hong, Christopher S., Chen, Ling-Chao, Zhang, Xin, Zhao, Fang-Ping, Wang, Yin, Wang, Yang, Zhou, Liang-Fu, Zhuang, Zhengping, Ng, Ho-Keung, Yan, Hai, Yao, Yu, Mao, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694799/
https://www.ncbi.nlm.nih.gov/pubmed/26314843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694799/
https://www.ncbi.nlm.nih.gov/pubmed/26314843

Ejemplares similares